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What is already known about this topic? Patients with asthma frequently have chronic rhinosinusitis (CRS) comorbidity,
and these patients are often difﬁcult to treat, with poor quality of life and few treatment options.
What does this article add to our knowledge? Dupilumab provides efﬁcacy and quality-of-life beneﬁts to patients with
asthma and comorbid CRS.
How does this study impact current management guidelines? Patients with asthma and comorbid CRS may gain
additional beneﬁts from dupilumab treatment as it targets type 2 inﬂammation associated with these comorbid conditions.
BACKGROUND: Dupilumab, a fully human monoclonal
antibody, blocks the shared receptor component for IL-4 and IL-13
signaling, key drivers of type 2 inﬂammation. In the phase 3
study (NCT02414854), add-on dupilumab 200mg/300 mg every 2
weeks, versus placebo, signiﬁcantly reduced severe asthma exacer-
bations and improved pre-bronchodilator forced expiratory volume
in 1 second (FEV1) and quality-of-life measures in patients with
uncontrolled, moderate-to-severe asthma, with greater efﬁcacy
observed in those with a high baseline type 2 phenotype.
OBJECTIVE: Toassess theefﬁcacyandsafetyofdupilumabinpatients
with uncontrolled, moderate-to-severe asthma with or without self-
reported comorbid chronic rhinosinusitis (CRS or non-CRS).
METHODS: Comorbid CRS was self-reported by patients using
an e-diary. Annualized severe exacerbation rates, changes from
baseline in pre- and post-bronchodilator FEV1, patient-reported
outcomes, type 2 biomarkers, and safety were assessed.
RESULTS: CRS was self-reported by 382 of 1902 (20.1%) pa-
tients. Dupilumab 200 mg/300 mg reduced annualized severe
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Abbreviations used
ACQ-5- 5-Item Asthma Control Questionnaire
AQLQ(S)- AsthmaQuality of Life Questionnaire (standardized version)
CI- Conﬁdence interval
CRS- Chronic rhinosinusitis
FeNO- Fractional exhaled nitric oxide
FEV1- Forced expiratory volume in 1 second
HLT- High Level Term




MedDRA-Medical Dictionary for Regulatory Activities
NP- Nasal polyps
PRO- Patient-reported outcome
q2w- Every 2 weeks
SD- Standard deviation
SE- Standard error
SNOT-22- 22-Item Sino-Nasal Outcome Test
TARC- Thymus and activation-regulated cytokine
TEAE- Treatment-emergent adverse event
exacerbation rates by 63%/61%, respectively, in patients with
CRS, and by 42%/40% in patients without CRS (all P < .001
vs placebo). Dupilumab also improved lung function and
patient-reported asthma control and quality of life, and
suppressed type 2 biomarkers versus placebo in both sub-
groups. Clinical responses were rapid, with near-maximal
responses observed at the earliest measured time points and
sustained at week 52. Improvements observed in the CRS
subgroup were similar to or numerically greater than those in
the non-CRS subgroup.
CONCLUSION: Dupilumab showed efﬁcacy and was generally
well tolerated in patients with uncontrolled, moderate-to-severe
asthma with or without CRS.  2019 The Authors. Published
by Elsevier Inc. on behalf of the American Academy of Allergy,
Asthma & Immunology. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/). (J Allergy Clin Immunol Pract 2020;8:527-39)
Key words: Chronic rhinosinusitis; Dupilumab; Efﬁcacy; Safety;
Asthma; Anti-IL-4; Anti-IL-13
Chronic rhinosinusitis (CRS) and asthma frequently coexist1;
CRS is associated with exacerbation-prone asthma, asthma
persistence, and reduced health-related quality of life
(HRQoL).2-4 Speciﬁcally, comorbid CRS was associated with
higher frequency of asthma exacerbations in an analysis of data
from the National Heart, Lung, and Blood Institute’s Severe
Asthma Research Program-3.2 Comorbid CRS has been linked
to lower HRQoL, as measured by the Mini Asthma Quality of
Life Questionnaire (mini-AQLQ) and the Euro Quality of Life
health questionnaire, compared with patients with asthma but no
CRS.4
Type 2 cytokines, speciﬁcally IL-4, IL-5, and IL-13, are
known to play important roles in the pathogenesis of CRS with
nasal polyps (NP) and atopic asthma,5-7 which represent type 2-
mediated mucosal inﬂammation of the upper and lower airways,
respectively.8 CRS without NP has also been associated with type
2 inﬂammation in a subset of patients.9
Dupilumab is a fully human, VelocImmune-derived10,11
monoclonal antibody that blocks the shared receptor component
of IL-4 and IL-13, thus inhibiting signaling of both IL-4 and
IL-13, key drivers of type 2 inﬂammatory diseases such as atopic
dermatitis, asthma, allergic rhinitis, and food allergies.12 Dupilu-
mab is approved by the US Food and Drug Administration13 as an
add-on maintenance treatment in patients with moderate-to-
severe asthma aged 12 years with an eosinophilic phenotype
or with oral corticosteroidedependent asthma. Dupilumab is
approved in Japan for patients aged 12 years with severe or re-
fractory bronchial asthma whose symptoms are inadequately
controlled with existing therapies,14 and by the European Medi-
cines Agency15 as an add-on maintenance treatment in patients
aged 12 years with type 2 severe asthma characterized by
increased blood eosinophils and/or raised fractional exhaled nitric
oxide (FeNO) who are inadequately controlled with high-dose
inhaled corticosteroid (ICS) plus another medicinal product for
maintenance treatment.16-18 Dupilumab is approved in the USA
as an add-on treatment in patients with inadequately controlled
CRS with NP,13 and adults in the European Union15 and other
countries.19-21
In the phase 3 LIBERTY ASTHMAQUEST study, dupilumab
reduced severe asthma exacerbations and showed a rapid and sus-
tained improvement in lung function in patients with uncontrolled,
moderate-to-severe asthma, with greater treatment effects observed
in patients with elevated baseline levels of blood eosinophils or
FeNO.17 In a phase 2a trial in patients with severe CRS with NP
refractory to intranasal corticosteroids, dupilumab signiﬁcantly
reduced polyp size and sinus opaciﬁcation/inﬂammation, improved
nasal congestion, nasal peak inspiratory ﬂow, sense of smell, and
HRQoL, and improved asthma control and lung function in a
subset of patients with comorbid asthma.22 These ﬁndings were
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conﬁrmed in 2 phase 3, placebo-controlled studies of dupilumab in
patients with severe CRS and NP refractory to systemic cortico-
steroids and/or surgery (NCT02912468, NCT02898454). After
24 weeks, dupilumab signiﬁcantly improved NP size, nasal opaci-
ﬁcation, nasal congestion, sense of smell, and HRQoL. In the
subgroups with comorbid asthma (n ¼ 276 [58%] and n ¼ 448
[60%], 2 phase 3 studies), dupilumab signiﬁcantly improved lung
function and asthma control.23,24
This post hoc analysis of the phase 3 LIBERTY ASTHMA
QUEST study17 assessed the effect of dupilumab on severe ex-
acerbations, lung function, patient-reported outcomes (PROs),
and type 2 biomarkers in patients with moderate-to-severe
asthma with and without comorbid CRS.
METHODS
Study design
LIBERTY ASTHMA QUEST (NCT02414854) is a previously
reported, phase 3, randomized, double-blinded, placebo-controlled
study assessing the effect of dupilumab in patients with uncon-
trolled, moderate-to-severe asthma.17
The study was conducted in accordance with the Declaration of
Helsinki, International Conference on Harmonization Good Clin-
ical Practice guidelines, and applicable regulatory requirements. An
independent data and safety monitoring committee conducted
blinded monitoring of patient safety data, and an institutional review
board or ethics committee at each study center oversaw trial conduct
and documentation. All patients provided written informed consent
before participating in the trial.
Study population
Complete inclusion and exclusion criteria are provided in this
article’s Online Repository at www.jaci-inpractice.org.17
This post hoc analysis reports data for the subgroup of patients
with CRS, deﬁned as patients with self-reported comorbid CRS
with or without NP as recorded in an e-diary at baseline. Patients
not meeting these criteria were deﬁned as non-CRS. Data were
also analyzed in subgroups of patients with baseline blood eosin-
ophils 150 cells/mL or 300 cells/mL, and baseline FeNO 25
ppb.
Study endpoints
Efﬁcacy endpoints were the annualized severe asthma exacerba-
tion rate and change from baseline in pre- and post-bronchodilator
forced expiratory volume in 1 second (FEV1). In addition, PROs
were assessed during the 52-week treatment period using the scores
from 3 patient-reported questionnaires: the 5-item Asthma Control
Questionnaire (ACQ-5), Asthma Quality of Life Questionnaire
(standardized version) (AQLQ[S]), and 22-item Sino-Nasal
Outcome Test (SNOT-22). The ACQ-5 is a measure of the level
of asthma control (global score 0-6, with higher scores indicating less
control), and the AQLQ(S) assesses the impact of asthma on
HRQoL (global score 0-7, with higher scores indicating better
HRQoL). The SNOT-22, administered only to patients self-
reporting CRS, measures the impact of sino-nasal disorders on
HRQoL (total score 0-110, with higher scores indicating greater
HRQoL impairment). Within-patient improvement in ACQ-5,
AQLQ(S), and SNOT-22 scores of at least 0.5, 0.5, and 8.9,
respectively, were considered clinically meaningful as deﬁned by the
questionnaire developers.25-28 Concentrations of the following bio-
markers of type 2 inﬂammation were also measured over the 52-
week treatment period in all patients: FeNO, serum total IgE,
serum thymus and activation-regulated chemokines (TARCs), and
peripheral blood eosinophils. Speciﬁc IgE for the following aero-
antigens was assessed at baseline: Aspergillus fumigatus, cat dander,
mite Dermatophagoides farinae, mite Dermatophagoides pteronyssinus,
dog dander, German cockroach, Oriental cockroach, Alternaria
tenuis/alternata, and Cladosporium herbarum/Hormodendrum.
Treatment-emergent adverse events (TEAEs) were reported for
the CRS and non-CRS subgroups, and safety data were analyzed
according to the treatment received.
Statistical analysis
Efﬁcacy analyses were performed in the intention-to-treat (ITT)
population, deﬁned as all patients who underwent randomization,
with data analyzed according to the assigned intervention.19 Within
each subgroup, annualized rates of severe exacerbations were derived
from negative binomial regression models, which included the total
number of events that occurred in the double-blind treatment period
(regardless of whether the patient was on treatment) as the response
variable. Covariates in the models included treatment group, age,
baseline blood eosinophil level, baseline ICS dose level, geographic
region, and number of severe exacerbations in the preceding year.
Changes from baseline in pre- and post-bronchodilator FEV1, ACQ-
5, AQLQ(S), and SNOT-22 scores were analyzed in each subgroup
using mixed-effects models with repeated measures, with age,
geographic region, baseline eosinophil level, baseline ICS dose level,
visit, treatment-by-visit interaction, baseline level of the corre-
sponding variable, and baseline-by-visit interaction as covariates.
Baseline height and sex were also included as covariates in analyses of
change from baseline in FEV1. Changes from baseline in type 2
inﬂammatory biomarkers in the exposed population, deﬁned as all
patients exposed to study medication, were summarized by
descriptive statistics and compared based on a rank analysis of the
covariance model adjusted for the baseline biomarker level, age, sex,
geographic region, baseline eosinophil level, and baseline ICS dose
level. A nominal P value of <.05 for the comparison between each
dupilumab dose and matched-volume placebo (within each sub-
group) was considered statistically signiﬁcant.
RESULTS
Baseline characteristics
Of 1902 patients with uncontrolled, moderate-to-severe
asthma in the ITT population, 382 (20.1%) self-reported co-
morbid CRS.
The baseline patient demographic and clinical characteristics
of the CRS and non-CRS subgroups are shown in Table I. The
subgroup with CRS was signiﬁcantly older than the non-CRS
subgroup at study baseline (mean [standard deviation, SD],
51.5 [12.1] vs 47.0 [15.9] years, respectively) and at asthma
onset (mean [SD], 31.7 [18.0] vs 25.8 [19.2] years, respectively)
(both comparisons P < .0001). Patients in this subgroup had
also experienced more asthma exacerbations in the past year
(mean [SD], 2.32 [2.29] vs 2.04 [2.12] non-CRS, P ¼ .03) and
had signiﬁcantly higher levels of the type 2 biomarkers, FeNO,
and peripheral blood eosinophils (both P < .0001), than those
in the non-CRS subgroup. Baseline total IgE levels were similar
between subgroups, with a smaller proportion of patients posi-
tive for 1 speciﬁc IgE in the CRS subgroup than in the non-
CRS subgroup (P < .0001). In general, other baseline de-
mographic and clinical characteristics were similar between the 2
subgroups.
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TABLE I. Baseline demographic and disease characteristics
Patients with asthma with CRS (n [ 382) Patients with asthma without CRS (n [ 1520)
P value, with CRS
vs without CRS

















Age, mean (SD), y 52.3 (12.0) 51.0 (10.6) 49.6 (11.8) 52.7 (13.5) 47.2 (16.3) 47.1 (16.2) 47.8 (15.4) 46.5 (15.8) <.0001
Female sex, n (%) 38 (60.3) 71 (56.3) 48 (68.6) 75 (61.0) 160 (63.0) 316 (62.6) 170 (67.7) 319 (62.5) .32
BMI, mean (SD), kg/m2 29.61 (5.86) 28.31 (5.47) 29.40 (6.18) 28.23 (5.67) 29.79 (7.57) 29.23 (6.75) 29.16 (7.16) 29.27 (6.89) .07
Age at onset of asthma, mean
(SD), y
33.4 (19.1) 32.3 (16.3) 29.7 (19.0) 31.3 (18.6) 25.7 (18.9) 25.8 (19.6) 26.8 (18.5) 25.4 (19.5) <.0001
Pre-bronchodilator FEV1, mean
(SD), L
1.81 (0.62) 1.88 (0.57) 1.70 (0.59) 1.68 (0.53) 1.75 (0.61) 1.76 (0.63) 1.76 (0.56) 1.81 (0.62) .82
Pre-bronchodilator FEV1, mean
(SD), % predicted
59.06 (12.92) 60.05 (12.92) 57.17 (13.66) 57.17 (14.05) 58.27 (13.31) 57.96 (13.64) 58.68 (13.94) 58.83 (13.38) .99
FEV1 reversibility, mean (SD), % 24.81 (15.06) 24.46 (18.74) 24.37 (15.71) 22.83 (16.64) 25.12 (19.60) 28.12 (23.66) 27.03 (18.14) 26.43 (25.17) .006
Exacerbations in the past year,
mean (SD), n
2.16 (1.58) 2.14 (1.91) 2.56 (2.38) 2.46 (2.84) 2.05 (1.58) 2.05 (2.82) 2.24 (1.97) 1.92 (1.51) .03
With ongoing atopic medical
condition,* n (%)
49 (77.8) 105 (83.3) 65 (92.9) 99 (80.5) 217 (85.4) 404 (80.0) 201 (80.1) 425 (83.3) .58
AQLQ(S) score, mean (SD)† 4.26 (1.02) 4.39 (0.98) 4.30 (1.05) 4.31 (1.06) 4.26 (1.02) 4.29 (1.10) 4.31 (1.02) 4.27 (1.05) .48
ACQ-5 score, mean (SD) 2.86 (0.70) 2.76 (0.80) 2.76 (0.73) 2.85 (0.76) 2.68 (0.73) 2.76 (0.80) 2.77 (0.78) 2.75 (0.76) .16
SNOT-22 score, mean (SD)z 44.77 (19.75) 41.30 (17.98) 43.81 (19.28) 42.76 (18.02) e e e e e




































With1 positive speciﬁc IgE,{ n (%) 30 (47.6) 68 (54.4) 34 (49.3) 60 (49.2) 161 (64.4) 306 (61.4) 159 (63.9) 320 (63.6) <.0001




































ACQ-5, 5-Item Asthma Control Questionnaire; AQLQ(S), Asthma Quality of Life Questionnaire (standardized version); BMI, body mass index; CRS, chronic rhinosinusitis; FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory
volume in 1 second; IQR, interquartile range; q2w, every 2 weeks; SD, standard deviation; SNOT-22, Sino-Nasal Outcome Test; TARC, thymus and activation-regulated chemokine.
Baseline blood eosinophil data were missing for 1 randomized patient receiving dupilumab 200 mg q2w and 1 randomized patient receiving placebo 2 mL/300 mg q2w and were excluded from efﬁcacy analyses.
*Ongoing atopic medical condition deﬁned as any of the following ongoing conditions: atopic dermatitis, allergic conjunctivitis or rhinitis, eosinophilic esophagitis, food allergy, hives; or has baseline total IgE 100 IU/mL and at least 1
aeroantigen-speciﬁc IgE is positive (0.35 IU/mL) at baseline.
†n ¼ 95 missing at baseline.
zn ¼ 45 missing at baseline.
xn ¼ 24 missing at baseline.
ǁn ¼ 20 missing at baseline.
{Speciﬁc IgE-positive deﬁned as at least 1 aeroantigen 0.35 IU/mL at baseline: Aspergillus fumigatus, cat dander, mite Dermatophagoides farinae, mite Dermatophagoides pteronyssinus, dog dander, German cockroach, Oriental
cockroach, Alternaria tenuis/alternata, Cladosporium herbarum/Hormodendrum. n ¼ 23 missing at baseline.
#n ¼ 28 missing at baseline.






































Annualized rate of severe asthma exacerbations
Dupilumab 200mgor 300mg administered every 2weeks (q2w)
signiﬁcantly reduced annualized rates of severe asthma exacerbations
compared with a matched-volume placebo (1.14 mL or 2.0 mL,
respectively) in patients with and without CRS (Figure 1, A), with
overall reductions of 63% (200mg q2w) and 61% (300mg q2w) in
the CRS subgroup (both P < .001), and 42% (200 mg q2w) and
40% (300 mg q2w) in the non-CRS subgroup (both P< .001). In
placebo-treated patients, the CRS subgroup had numerically higher
adjusted annualized rates of severe asthma exacerbations than the
non-CRS subgroup: for 1.14 and 2.0 mL q2w, the CRS subgroup
had rates (95% conﬁdence interval [CI]) of 1.25 (0.85-1.82) and
1.25 (0.88-1.78), compared with the non-CRS subgroup’s rates of
0.79 (0.64-0.97) and 0.89 (0.72-1.10).
In general, dupilumab 200 and 300 mg q2w versus a
matched-volume placebo showed a numerically greater reduction
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FIGURE 1. Effect of dupilumab on annualized severe exacerbation rates.A, In the overall ITTCRS and non-CRS subgroups. B, In thosewith
baseline blood eosinophils 150 cells/mL. C, In those with baseline blood eosinophils 300 cells/mL. D, In those with baseline FeNO 25
ppb. CI, Confidence interval; CRS, chronic rhinosinusitis; FeNO, fractional exhaled nitric oxide; ITT, intention-to-treat; q2w, every 2 weeks.
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in severe exacerbation rate in the CRS subgroup than in the non-
CRS subgroup in patients with baseline blood eosinophils 150
cells/mL (Figure 1, B) and 300 cells/mL (Figure 1, C), and in
those with baseline FeNO 25 ppb (Figure 1, D).
Pre-bronchodilator FEV1
Dupilumab 200 and 300 mg q2w treatment resulted in rapid
and sustained improvements in pre-bronchodilator FEV1 versus a
matched-volume placebo in both the CRS and non-CRS sub-
groups (Figure 2, A, and Table E1, available in this article’s Online
Repository at www.jaci-inpractice.org). In the CRS subgroup,
dupilumab 200 and 300 mg q2w signiﬁcantly improved pre-
bronchodilator FEV1 at week 2 with a least-squares (LS) mean
change from baseline difference (95%CI) versus placebo of 0.20 L
(0.10-0.31, P ¼ .0001) and 0.21 L (0.11-0.31, P < .0001),
respectively; at week 12, 0.18 L (0.06-0.30, P¼ .004) and 0.15 L
(0.04-0.27, P ¼ .01), respectively; and at week 52, 0.28 L (0.15-
0.41, P < .0001) and 0.16 L (0.03-0.28, P ¼ .02), respectively.
Similar results were seen in the non-CRS subgroup at week 2 (LS
mean change from baseline difference vs placebo [95% CI] for
dupilumab 200 and 300mg, respectively, 0.13 L [0.07-0.18], P<
.0001; 0.13 L [0.08-0.19], P < .0001); week 12 (0.13 L [0.07-
0.18], P < .0001; 0.12 L [0.06-0.18], P < .0001); and week 52
(0.17 L [0.11-0.24], P < .0001; 0.12 L [0.06-0.19], P ¼ .0002).
In both the CRS and non-CRS subgroups, treatment effects
with 300 mg dupilumab versus a matched-volume placebo on
change from baseline in pre-bronchodilator FEV1 at week 12
were numerically greater in patients with baseline blood eosin-
ophils 300 cells/mL and with baseline FeNO 25 ppb
(Figure 2, B).
Post-bronchodilator FEV1
Dupilumab resulted in rapid and sustained improvements in
post-bronchodilator FEV1 versus a matched-volume placebo in
both theCRS and non-CRS subgroups (Figure 3,A, andTable E2,
available in this article’s Online Repository at www.jaci-inpractice.
org). In the CRS subgroup, dupilumab signiﬁcantly improved
post-bronchodilator FEV1 by week 2 with an LS mean change
from baseline difference (95% CI) versus placebo of 0.20 L (0.09-
0.30, P ¼ .0002) and 0.21 L (0.11-0.31, P < .0001) for dupi-
lumab 200 and 300 mg q2w, respectively. These improvements
continued through week 12 (0.12 L [0.01-0.23], P ¼ .03; 0.18 L
[0.07-0.28], P ¼ .0009) and week 52 (0.27 L [0.15-0.39], P <
.0001; 0.14 L [0.03-0.26], P ¼ .02). Similarly, in the non-CRS
subgroup, dupilumab signiﬁcantly improved post-
bronchodilator FEV1 by week 2 (LS mean change from
baseline difference vs placebo [95% CI] of 0.15 L [0.11-0.20],
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FIGURE 2. Effect of dupilumab on pre-bronchodilator FEV1. A, In the overall ITT CRS and non-CRS subgroups. B, In those with baseline
blood eosinophils 150 cells/mL, 300 cells/mL, and baseline FeNO 25 ppb. CI, Confidence interval; CRS, chronic rhinosinusitis; FeNO,
fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; ITT, intention-to-treat; LS, least squares; q2w, every 2 weeks;
SE, standard error.
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week 12 (0.14 L [0.09-0.19], P< .0001; 0.09 L [0.03-0.14], P¼
.001) and week 52 (0.17 L [0.11-0.23], P< .0001; 0.13 L [0.07-
0.18], P < .0001).
In both the CRS and non-CRS subgroups, treatment effects on
post-bronchodilator FEV1 at week 12 were numerically greater in
patients with baseline blood eosinophils 300 cells/mL and with
baseline FeNO 25 ppb (Figure 3, B).
ACQ-5 score
Dupilumab 200 and 300 mg q2w versus a matched-volume
placebo improved asthma control as assessed by ACQ-5 scores
in the CRS and non-CRS subgroups during the treatment period
(P< .05, most comparisons) (Figure 4, A, and Table E3, available
in this article’s Online Repository at www.jaci-inpractice.org). In
the CRS subgroup, the LS mean change from baseline at week 2
was 0.93 (standard error [SE] 0.08, difference vs placebo [95%
CI] 0.32 [0.59 to 0.05]; P ¼ .02) and 1.14 (SE 0.08,
difference vs placebo [95% CI] 0.63 [0.89 to 0.37]; P <
.0001) for dupilumab 200 and 300 mg, respectively. Improve-
ment was sustained through week 52 by 1.75 (SE 0.09, differ-
ence vs placebo [95% CI] 0.60 [0.90 to 0.30]; P ¼ .0001)
and 1.75 (SE 0.09, difference vs placebo [95% CI] 0.54
[0.83 to 0.25]; P ¼ .0003) for dupilumab 200 and 300 mg,
respectively. Similar results were seen in the non-CRS subgroup at
week 2 at0.88 (SE 0.04, difference vs placebo [95% CI]0.34
[0.47 to 0.20]; P < .0001) and 0.86 (SE 0.04, 0.23
[0.36 to 0.09]; P ¼ .001) and week 52 at 1.48 (SE 0.05,
difference vs placebo [95% CI] 0.33 [0.49 to 0.18]; P <
.0001) and 1.45 (SE 0.05, difference vs placebo [95%
CI]0.14 [0.29 to 0.02]; P¼ .09) for dupilumab 200 and 300
mg, respectively.
For both dupilumab regimens, the change in ACQ-5 scores
from baseline to week 52 in patients with asthma with CRS
exceeded the clinically meaningful difference of 0.5 for this
measure.25,26 The observed effects of dupilumab on ACQ-5
scores at week 52 were numerically greater in the CRS sub-
group than in the non-CRS subgroup.
AQLQ(S) score
In general, both dupilumab regimens signiﬁcantly (P < .05,
most comparisons) improved HRQoL as assessed by AQLQ(S)
scores versus a matched-volume placebo in the CRS and non-CRS
subgroups during the treatment period (Figure 4, B, and
Table E4, available in this article’s Online Repository at www.jaci-
inpractice.org). In the CRS subgroup, the LS mean change from
baseline at week 12 was improved by 1.23 (SE 0.08, difference vs
placebo [95% CI] 0.39 [0.10-0.68]; P¼ .008) and 1.16 (SE 0.09,
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FIGURE 3. Effect of dupilumab on post-bronchodilator FEV1. A, In the overall ITT CRS and non-CRS subgroups. B, In those with baseline
blood eosinophils 150 cells/mL, 300 cells/mL, and baseline FeNO 25 ppb. CI, Confidence interval; CRS, chronic rhinosinusitis; FeNO,
fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; ITT, intention-to-treat; LS, least squares; q2w, every 2 weeks;
SE, standard error.
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dupilumab 200 and 300 mg, respectively. Improvement was
sustained through week 52 by 1.46 (SE 0.09, difference vs placebo
[95% CI] 0.58 [0.28-0.88]; P ¼ .0002) and 1.44 (SE 0.09,
difference vs placebo [95% CI] 0.57 [0.29-0.86]; P ¼ .0001) for
dupilumab 200 and 300 mg, respectively. In the non-CRS sub-
group, the LS mean change from baseline at week 12 was
improved by 1.06 (SE 0.04, difference vs placebo [95% CI] 0.18
[0.04-0.32]; P ¼ .01) and 1.07 (SE 0.04, difference vs placebo
[95% CI] 0.19 [0.05-0.33]; P ¼ .009) for dupilumab 200 and
300 mg, respectively. Improvement was sustained through week
52 by 1.23 (SE 0.05, difference vs placebo [95% CI] 0.21 [0.05-
0.37]; P ¼ .01) and 1.25 (SE 0.05, difference vs placebo [95%
CI] 0.19 [0.03-0.35]; P ¼ .02) for dupilumab 200 and 300 mg,
respectively.
For both dupilumab regimens, the change in AQLQ(S) scores
from baseline to week 52 in patients with asthma with CRS
exceeded the clinically meaningful difference of 0.5 for this
measure.27 The observed effect of dupilumab on AQLQ(S) score
at week 52 was numerically greater in the CRS subgroup than in
the non-CRS subgroup.
SNOT-22 score
Patients treated with dupilumab versus placebo had signiﬁcant
improvement in CRS-speciﬁc symptoms and HRQoL as assessed
by SNOT-22 scores during the treatment period (P < .05, all
comparisons) (Figure 4, C, and Table E5, available in this arti-
cle’s Online Repository at www.jaci-inpractice.org). The LS
mean change from baseline at week 12 was improved by 13.81
(SE 1.49, difference vs placebo [95% CI] 8.13 [13.28
to 2.98]; P ¼ .002) and 15.77 (SE 1.57, difference vs pla-
cebo [95% CI] 6.02 [10.93 to 1.10]; P ¼ .02) for dupi-
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FIGURE 4. Effect of dupilumab on (A) asthma control and (B) quality of life in patients with asthma with and without CRS, and (C) on
sinonasal outcomes in patients with CRS. ACQ-5, 5-Item Asthma Control Questionnaire; AQLQ(S), Asthma Quality of Life Questionnaire
(standardized version); CRS, chronic rhinosinusitis; LS, least squares; q2w, every 2 weeks; SE, standard error; SNOT-22, Sino-Nasal
Outcome Test.
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sustained through week 52 by 16.35 (SE 1.65, difference vs
placebo [95% CI] 11.88 [17.59 to 6.18]; P < .0001)
and 17.86 (SE 1.72, difference vs placebo [95% CI] 10.32
[15.77 to 4.87]; P ¼ .0002) for dupilumab 200 and 300 mg,
respectively.
The magnitude of change in SNOT-22 scores from baseline
to week 52 in dupilumab-treated patients exceeded 8.9, the
difference regarded as clinically meaningful for this measure.28
Type 2 biomarkers
Rapid and sustained suppression of airway (FeNO) and sys-
temic (total IgE, TARC) type 2 inﬂammatory biomarkers were
observed in all dupilumab-treated patients. In both CRS and
non-CRS subgroups, the change from baseline in FeNO levels
with either dupilumab q2w dose regimen was signiﬁcantly
greater than in placebo-treated patients, in whom no change in
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FIGURE 5. Effect of dupilumab on (A) FeNO, (B) serum total IgE, (C) TARC, and (D) blood eosinophils during the 52-week treatment period
in CRS and non-CRS subgroups. CI, Confidence interval; CRS, chronic rhinosinusitis; FeNO, fractional exhaled nitric oxide; q2w, every 2
weeks; SE, standard error; TARC, thymus and activation-regulated cytokine.
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sustained over the 52-week study period (P < .01 all compari-
sons; Figure 5, A, and Table E6, available in this article’s Online
Repository at www.jaci-inpractice.org).
For IgE and TARC (Figure 5, B and C, and Tables E7 and
E8, available in this article’s Online Repository at www.jaci-
inpractice.org), signiﬁcant differences in reductions from base-
line versus placebo were observed in both subgroups by week 12,
with these differences evident throughout the 52-week treatment
period (P < .01 for all IgE and TARC comparisons). No changes
in serum total IgE or TARC were observed in placebo-treated
patients.
No changes from baseline in blood eosinophil levels were
observed throughout the study in non-CRS patients irrespective
of treatment, whereas mild elevations were observed in CRS
patients treated with dupilumab (Figure 5, D, and Table E9,
available in this article’s Online Repository at www.jaci-
inpractice.org).
Safety
Rates of TEAEs were similar across treatment groups (placebo
83.1%; dupilumab 81.0%) in the overall population, as reported
previously.19 Injection-site reactions (Medical Dictionary for
Regulatory Activities [MedDRA] High Level Term [HLT]) were
the most frequent TEAEs, occurring at higher rates in
dupilumab-treated patients than in placebo-treated patients
(dupilumab 16.8%; placebo 7.9%).19
In the CRS subgroup, serious TEAEs occurred in 12.8% of
patients who received a placebo and in 7.2% of patients treated
with dupilumab; in the non-CRS subgroup, the proportion of
patients with serious TEAEs was similar in both treatment
groups (7.2% placebo vs 8.5% dupilumab). Injection-site re-
actions (MedDRA HLT) occurred more frequently in
dupilumab-treated patients (dupilumab vs placebo, 22.1% vs
10.5% and 15.5% vs 7.2% in the CRS and non-CRS subgroups,
respectively) (Table II).
In this analysis, the incidence of TEAEs was higher in the
CRS subgroup (placebo 89.5%; dupilumab 83.5%) than in the
non-CRS subgroup (placebo 81.4%; dupilumab 80.4%). In
both subgroups, irrespective of treatment, viral upper respiratory
tract infections were the most frequently reported TEAE
(MedDRA Preferred Term) (Table III).
DISCUSSION
This post hoc analysis of the LIBERTY ASTHMA QUEST
study demonstrated that dupilumab treatment signiﬁcantly
reduced severe asthma exacerbations and improved pre- and
post-bronchodilator FEV1 in patients with moderate-to-severe
asthma with and without comorbid CRS, with apparently
greater improvements observed in the subgroups of patients with
elevated baseline blood eosinophils and FeNO. Dupilumab
improved patient-reported asthma control and HRQoL and
suppressed type 2 inﬂammatory biomarkers in both subgroups.
It also improved sino-nasal symptoms and HRQoL, as assessed
by SNOT-22, in patients with CRS. The results obtained for the
2 subgroups of patients were consistent with the overall study
results reported for the ITT population.17
Patients with asthma with CRS are difﬁcult to treat and have
more severe disease.2,3 This was reﬂected by their signiﬁcantly
greater severe exacerbation history, and signiﬁcantly higher levels
of the type 2 inﬂammatory biomarkers, FeNO, and blood eosin-
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consistent with previously published observations of increased
expression of inﬂammatory biomarkers found in nasal polyp tissue
of patients with CRS.29
Consistent with its mechanism of action, dupilumab treat-
ment provided rapid and sustained suppression of both local and
systemic type 2 inﬂammatory biomarkers. At week 52 in both
subgroups, the median FeNO levels in dupilumab-treated pa-
tients were consistent with previously reported FeNO levels for
healthy patients (25 ppb).30 A transient increase in mean pe-
ripheral blood eosinophils was observed in the overall ITT
population, and it declined to baseline levels during treatment.17
However, in this analysis, patients with CRS had higher median
blood eosinophil levels at baseline and throughout the treatment
period than patients without CRS, consistent with a type 2 in-
ﬂammatory phenotype.
Interestingly, with dupilumab treatment, the magnitude of
reductions in severe asthma exacerbations and improvement in
FEV1 from baseline was greater in the CRS subgroup than the
non-CRS subgroup. This greater reduction may be due to the
simultaneous symptom control of type 2-mediated inﬂammation
of both upper and lower airways by dupilumab, leading to im-
provements in both CRS (upper airway) and asthma (lower
airway) outcome measures. Recent studies have demonstrated
that targeting the IL-5 pathway may be efﬁcacious in the treat-
ment of asthma in a subgroup of patients with severe eosinophilic
asthma with comorbid CRS.31-33 The numerical difference in
efﬁcacy between the CRS and non-CRS groups could also result
from between-group differences in baseline characteristics such as
exacerbation rate and type 2 biomarkers. It is also noteworthy
that dupilumab resulted in a numerically greater reduction in
severe exacerbations in the subgroup with CRS, given that this
subgroup had a higher severe exacerbation rate and type 2
burden at baseline compared with the non-CRS subgroup.
The ﬁndings reported here support and extend the data
obtained from a previously published proof-of-concept, phase
2, randomized, placebo-controlled study of dupilumab in pa-
tients with CRS and NP.22 Adding dupilumab 300 mg q2w to
intranasal corticosteroid therapy signiﬁcantly reduced the
burden of NP while improving FEV1 and asthma control, as
well as sense of smell, sinus computed tomography scans, and
quality of life in patients with CRS, NP, and comorbid asthma.
Phase 3 studies of dupilumab in CRS and NP have recently
been completed, conﬁrming and extending these positive
results.23,24
Consistent with safety in the overall population of the
QUEST phase 3 study,17 dupilumab had an acceptable safety
proﬁle in patients with and without CRS and was generally well
tolerated. Injection-site reactions occurred more frequently in
dupilumab-treated patients than in placebo-treated patients,
being more frequent in patients with CRS than in those without
CRS.
A major limitation of this analysis is that the diagnosis of CRS
was based on patient self-reporting rather than clinician diag-
nosis. Patients with past but no current symptoms of CRS may
not have reported themselves as having CRS and therefore may
have been included in the non-CRS group. In addition, we were
unable to evaluate any differences in outcomes between CRS
with and without NP, as this level of data was not obtained.
TABLE III. Treatment-emergent adverse events (MedDRA PT) in 5% of patients in the CRS and non-CRS subgroups in the safety
population
n (%)
1.14 mL/200 mg q2w 2 mL/300 mg q2w Combined
Placebo Dupilumab Placebo Dupilumab Placebo Dupilumab
TEAEs occurring in 5% of patients in any group*
CRS (n ¼ 382) (n ¼ 63) (n ¼ 126) (n ¼ 70) (n ¼ 123) (n ¼ 133) (n ¼ 249)
Viral upper respiratory tract infection 7 (11.1) 24 (19.0) 16 (22.9) 21 (17.1) 23 (17.3) 45 (18.1)
Injection site erythema 3 (4.8) 22 (17.5) 7 (10.0) 26 (21.1) 10 (7.5) 48 (19.3)
Bronchitis 12 (19.0) 15 (11.9) 10 (14.3) 18 (14.6) 22 (16.5) 33 (13.3)
Upper respiratory tract infection 11 (17.5) 13 (10.3) 16 (22.9) 17 (13.8) 27 (20.3) 30 (12.0)
Sinusitis 8 (12.7) 10 (7.9) 12 (17.1) 8 (6.5) 20 (15.0) 18 (7.2)
Inﬂuenza 7 (11.1) 11 (8.7) 6 (8.6) 12 (9.8) 13 (9.8) 23 (9.2)
Headache 7 (11.1) 8 (6.3) 7 (10.0) 9 (7.3) 14 (10.5) 17 (6.8)
Back pain 3 (4.8) 8 (6.3) 2 (2.9) 8 (6.5) 5 (3.8) 16 (6.4)
Non-CRS (n ¼ 1515) (n ¼ 250) (n ¼ 505) (n ¼ 251) (n ¼ 509) (n ¼ 501) (n ¼ 1014)
Viral upper respiratory tract infection 53 (21.2) 95 (18.8) 48 (19.1) 90 (17.7) 101 (20.2) 185 (18.2)
Upper respiratory tract infection 26 (10.4) 56 (11.1) 33 (13.1) 60 (11.8) 59 (11.8) 116 (11.4)
Bronchitis 35 (14.0) 58 (11.5) 32 (12.7) 53 (10.4) 67 (13.4) 111 (10.9)
Injection site erythema 10 (4.0) 54 (10.7) 15 (6.0) 72 (14.1) 25 (5.0) 126 (12.4)
Headache 19 (7.6) 38 (7.5) 18 (7.2) 31 (6.1) 37 (7.4) 69 (6.8)
Accidental overdose† 16 (6.4) 29 (5.7) 14 (5.6) 31 (6.1) 30 (6.0) 60 (5.9)
Inﬂuenza 22 (8.8) 25 (5.0) 16 (6.4) 26 (5.1) 38 (7.6) 51 (5.0)
Sinusitis 19 (7.6) 26 (5.1) 17 (6.8) 18 (3.5) 36 (7.2) 44 (4.3)
CRS, Chronic rhinosinusitis; MedDRA, Medical Dictionary for Regulatory Activities; PT, Preferred Term; q2w, every 2 weeks; TEAE, treatment-emergent adverse event.
*Adverse events in this category were reported according to the preferred terms in the MedDRA, version 20.0.
†Accidental overdose is coded in MedDRA as an overdose arising from a medication error (eg, drug reconstitution error, incorrect dose, or incorrect dosing interval) and not
associated with clinical symptoms.
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Nonetheless, the signiﬁcant baseline differences between the
subgroups with and without a diagnosis of CRS (older age, more
asthma exacerbations in the previous year, higher levels of type 2
biomarkers, smaller proportion positive for 1 speciﬁc IgE)
suggest that patient self-reporting identiﬁed a speciﬁc phenotype.
Recent evidence indicates that type 2 inﬂammation is present in
patients with CRS with and without NP.9 Although our study
was not speciﬁcally designed to compare patients with and
without CRS, the power was sufﬁcient for a careful and rigorous
evaluation of asthma clinical outcomes, biomarkers, and PROs in
this population with comorbid disease. In addition, studies of
reslizumab and benralizumab in patients with asthma also relied
on self-reporting to identify patients with CRS with or without
NP.33,34
This post hoc analysis suggests that adding dupilumab 200 or
300 mg q2w to medium-to-high-dose ICS plus long-acting
b2-agonist therapy was effective and well tolerated in patients
with uncontrolled, moderate-to-severe asthma with and without
comorbid CRS. Improvements in asthma control occurred
rapidly and were sustained over the 52-week study period.
Notably, the clinical beneﬁts associated with dupilumab in terms
of efﬁcacy and improved quality of life were particularly evident
in the subgroup of patients with comorbid asthma and CRS.
These patients represent a difﬁcult-to-treat subpopulation of
patients with asthma, with high levels of inﬂammatory bio-
markers and baseline disease burden, and increased risk of
asthma exacerbations. Dupilumab was particularly efﬁcacious in
these patients, providing evidence of improving symptoms in
comorbidities of both the upper and lower airways.
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TABLE E1. LS mean change from baseline in pre-bronchodilator FEV1 (L) during the 52-week treatment period in patients with asthma with CRS and patients with asthma without CRS
LS mean change
from baseline
Patients with asthma with CRS (n [ 382) Patients with asthma without CRS (n [ 1520)
1.14 mL/200 mg q2w 2.0 mL/300 mg q2w 1.14 mL/200 mg q2w 2.0 mL/300 mg q2w
Placebo (n [ 63) Dupilumab (n [ 126) Placebo (n [ 70) Dupilumab (n [ 123) Placebo (n [ 254) Dupilumab (n [ 505) Placebo (n [ 251) Dupilumab (n [ 510)
Baseline, n 63 126 70 123 254 505 251 510
Mean (SD) 1.81 (0.62) 1.88 (0.57) 1.70 (0.59) 1.68 (0.53) 1.75 (0.61) 1.76 (0.63) 1.76 (0.56) 1.81 (0.62)
Week 2, n 63 122 68 121 252 488 245 504
LS mean (SE) 0.06 (0.04) 0.26 (0.03) 0.07 (0.04) 0.28 (0.03) 0.12 (0.02) 0.25 (0.02) 0.15 (0.02) 0.28 (0.02)
LS mean difference
vs placebo (95% CI)
0.20 (0.10 to 0.31) 0.21 (0.11 to 0.31) 0.13 (0.07 to 0.18) 0.13 (0.08 to 0.19)
P value .0001 <.0001 <.0001 <.0001
Week 12, n 62 124 70 116 245 487 243 494
LS mean (SE) 0.20 (0.05) 0.37 (0.04) 0.18 (0.05) 0.33 (0.04) 0.18 (0.02) 0.31 (0.02) 0.22 (0.03) 0.34 (0.02)
LS mean difference
vs placebo (95% CI)
0.18 (0.06 to 0.30) 0.15 (0.04 to 0.27) 0.13 (0.07 to 0.18) 0.12 (0.06 to 0.18)
P value .0039 .0107 <.0001 <.0001
Week 24, n 61 120 64 117 239 479 232 479
LS mean (SE) 0.14 (0.05) 0.41 (0.04) 0.23 (0.05) 0.34 (0.04) 0.18 (0.03) 0.32 (0.02) 0.21 (0.03) 0.33 (0.02)
LS mean difference
vs placebo (95% CI)
0.27 (0.15 to 0.39) 0.11 (0.01 to 0.22) 0.14 (0.08 to 0.20) 0.11 (0.05 to 0.17)
P value <.0001 .0754 <.0001 .0005
Week 52, n 52 99 57 98 188 378 193 390
LS mean (SE) 0.14 (0.06) 0.42 (0.04) 0.19 (0.05) 0.34 (0.04) 0.17 (0.03) 0.34 (0.02) 0.24 (0.03) 0.36 (0.02)
LS mean difference
vs placebo (95% CI)
0.28 (0.15 to 0.41) 0.16 (0.03 to 0.28) 0.17 (0.11 to 0.24) 0.12 (0.06 to 0.19)
P value <.0001 .0156 <.0001 .0002
CI, Conﬁdence interval; CRS, chronic rhinosinusitis; FEV1, forced expiratory volume in 1 second; LS, least squares; q2w, every 2 weeks; SD, standard deviation; SE, standard error.








































TABLE E2. LS mean change from baseline in post-bronchodilator FEV1 (L) during the 52-week treatment period in patients with asthma with CRS and patients with asthma without CRS
LS mean change from baseline
Patients with asthma patients with CRS (n [ 382) Patients with asthma without CRS (n [ 1520)
1.14 mL/200 mg q2w 2.0 mL/300 mg q2w 1.14 mL/200 mg q2w 2.0 mL/300 mg q2w
Placebo (n [ 63) Dupilumab (n [ 126) Placebo (n [ 70) Dupilumab (n [ 123) Placebo (n [ 254) Dupilumab (n [ 505) Placebo (n [ 251) Dupilumab (n [ 510)
Baseline, n 63 126 70 123 254 505 251 510
Mean (SD) 2.16 (0.70) 2.24 (0.70) 2.08 (0.69) 2.02 (0.64) 2.16 (0.71) 2.14 (0.75) 2.15 (0.69) 2.21 (0.74)
Week 2, n 61 123 68 117 249 486 243 500
LS mean (SE) 0.03 (0.04) 0.17 (0.03) 0.08 (0.04) 0.13 (0.03) 0.05 (0.02) 0.11 (0.02) 0.00 (0.02) 0.11 (0.01)
LS mean difference
vs placebo (95% CI)
0.20 (0.09 to 0.30) 0.21 (0.11 to 0.31) 0.15 (0.11 to 0.20) 0.11 (0.06 to 0.16)
P value .0002 <.0001 <.0001 <.0001
Week 12, n 61 124 69 118 244 486 244 494
LS mean (SE) 0.08 (0.05) 0.20 (0.03) 0.00 (0.04) 0.18 (0.03) 0.01 (0.02) 0.13 (0.02) 0.05 (0.02) 0.13 (0.02)
LS mean difference
vs placebo (95% CI)
0.12 (0.01 to 0.23) 0.18 (0.07 to 0.28) 0.14 (0.09 to 0.19) 0.09 (0.03 to 0.14)
P value .0320 .0009 <.0001 .0011
Week 24, n 62 122 65 120 240 477 237 481
LS mean (SE) 0.01 (0.05) 0.20 (0.03) 0.05 (0.04) 0.16 (0.03) 0.03 (0.02) 0.15 (0.02) 0.00 (0.02) 0.12 (0.02)
LS mean difference
vs placebo (95% CI)
0.19 (0.08 to 0.30) 0.12 (0.01 to 0.22) 0.18 (0.12 to 0.23) 0.12 (0.06 to 0.18)
P value .0008 .0367 <.0001 <.0001
Week 52, n 52 103 56 104 187 396 199 390
LS mean (SE) 0.06 (0.05) 0.21 (0.04) 0.02 (0.05) 0.13 (0.04) 0.03 (0.02) 0.14 (0.02) 0.01 (0.02) 0.14 (0.02)
LS mean difference
vs placebo (95% CI)
0.27 (0.15 to 0.39) 0.14 (0.03 to 0.26) 0.17 (0.11 to 0.23) 0.13 (0.07 to 0.18)
P value <.0001 .0173 <.0001 <.0001
CI, Conﬁdence interval; CRS, chronic rhinosinusitis; FEV1, forced expiratory volume in 1 second; LS, least squares; q2w, every 2 weeks; SD, standard deviation; SE, standard error.











































TABLE E3. LS mean change from baseline in ACQ-5 scores during the 52-week treatment period in patients with asthma with CRS and patients with asthma without CRS
LS mean change from baseline
Patients with asthma patients with CRS (n [ 382) Patients with asthma without CRS (n [ 1520)
1.14 mL/200 mg q2w 2.0 mL/300 mg q2w 1.14 mL/200 mg q2w 2.0 mL/300 mg q2w
Placebo (n [ 63)
Dupilumab





Baseline, n 63 126 70 123 254 505 251 510
Mean (SD) 2.86 (0.70) 2.76 (0.80) 2.76 (0.73) 2.85 (0.76) 2.68 (0.73) 2.76 (0.80) 2.77 (0.78) 2.75 (0.76)
Week 2, n 61 122 66 118 243 477 239 497
LS mean (SE) 0.62 (0.11) 0.93 (0.08) 0.51 (0.11) 1.14 (0.08) 0.54 (0.06) 0.88 (0.04) 0.63 (0.06) 0.86 (0.04)
LS mean difference
vs placebo (95% CI)
0.32
(0.59 to 0.05)
0.63 (0.89 to 0.37) 0.34 (0.47 to 0.20) 0.23 (0.36 to 0.09)
P value .0201 <.0001 <.0001 .0010
Week 12, n 62 125 69 115 241 480 243 488
LS mean (SE) 1.02 (0.12) 1.57 (0.09) 1.28 (0.12) 1.62 (0.09) 1.02 (0.06) 1.30 (0.04) 1.05 (0.06) 1.30 (0.04)
LS mean difference
vs placebo (95% CI)
0.55
(0.84 to 0.26)
0.34 (0.62 to 0.06) 0.28 (0.42 to 0.13) 0.24 (0.39 to 0.10)
P value .0002 .0187 .0002 .0011
Week 24, n 61 120 65 115 235 470 232 470
LS mean (SE) 1.04 (0.13) 1.56 (0.09) 1.23 (0.12) 1.73 (0.09) 1.10 (0.06) 1.41 (0.05) 1.20 (0.06) 1.31 (0.05)
LS mean difference
vs placebo (95% CI)
0.52
(0.82 to 0.21)
0.50 (0.80 to 0.20) 0.31 (0.46 to 0.15) 0.11 (0.26 to 0.04)
P value .0009 .0010 <.0001 .1552
Week 52, n 50 96 55 94 186 374 190 383
LS mean (SE) 1.15 (0.13) 1.75 (0.09) 1.21 (0.12) 1.75 (0.09) 1.15 (0.07) 1.48 (0.05) 1.32 (0.07) 1.45 (0.05)
LS mean difference
vs placebo (95% CI)
0.60
(0.90 to 0.30)
0.54 (0.83 to 0.25) 0.33 (0.49 to 0.18) 0.14 (0.29 to 0.02)
P value .0001 .0003 <.0001 .0877
ACQ-5, 5-Item Asthma Control Questionnaire; CI, conﬁdence interval; CRS, chronic rhinosinusitis; LS, least squares; q2w, every 2 weeks; SD, standard deviation; SE, standard error.







































TABLE E4. LS mean change from baseline in AQLQ(S) scores during the 52-week treatment period in patients with asthma with CRS and patients with asthma without CRS
LS mean change from baseline
Patients with asthma with CRS (n [ 382) Patients with asthma without CRS (n [ 1520)
1.14 mL/200 mg q2w 2.0 mL/300 mg q2w 1.14 mL/200 mg q2w 2.0 mL/300 mg q2w
Placebo (n [ 63) Dupilumab (n [ 126) Placebo (n [ 70) Dupilumab (n [ 123) Placebo (n [ 254) Dupilumab (n [ 505) Placebo (n [ 251) Dupilumab (n [ 510)
Baseline, n 59 121 70 117 240 470 244 486
Mean (SD) 4.26 (1.02) 4.39 (0.98) 4.30 (1.05) 4.31 (1.06) 4.26 (1.02) 4.29 (1.10) 4.31 (1.02) 4.27 (1.05)
Week 12, n 57 120 69 113 229 453 239 473
LS mean (SE) 0.84 (0.12) 1.23 (0.08) 1.07 (0.11) 1.16 (0.09) 0.88 (0.06) 1.06 (0.04) 0.89 (0.06) 1.07 (0.04)
LS mean difference
vs placebo (95% CI)
0.39 (0.10 to 0.68) 0.09 (0.18 to 0.36) 0.18 (0.04 to 0.32) 0.19 (0.05 to 0.33)
P value .0076 .5221 .0145 .0092
Week 24, n 58 118 66 113 223 442 229 456
LS mean (SE) 0.84 (0.12) 1.17 (0.08) 0.95 (0.11) 1.38 (0.09) 0.96 (0.07) 1.12 (0.05) 1.01 (0.07) 1.09 (0.05)
LS mean difference
vs placebo (95% CI)
0.33 (0.05 to 0.62) 0.43 (0.16 to 0.70) 0.16 (0.01 to 0.32) 0.08 (0.07 to 0.23)
P value .0209 .0022 .0382 .2971
Week 52, n 47 96 55 95 177 369 188 364
LS mean (SE) 0.88 (0.13) 1.46 (0.09) 0.87 (0.12) 1.44 (0.09) 1.02 (0.07) 1.23 (0.05) 1.06 (0.07) 1.25 (0.05)
LS mean difference
vs placebo (95% CI)
0.58 (0.28 to 0.88) 0.57 (0.29 to 0.86) 0.21 (0.05 to 0.37) 0.19 (0.03 to 0.35)
P value .0002 .0001 .0118 .0215
AQLQ(S), Asthma Quality of Life Questionnaire (standardized version); CI, conﬁdence interval; CRS, chronic rhinosinusitis; LS, least squares; q2w, every 2 weeks; SD, standard deviation; SE, standard error.











































TABLE E5. LS mean change from baseline in SNOT-22 scores during the 52-week treatment period in patients with asthma with CRS
LS mean change from baseline
Patients with asthma with CRS (n [ 382)
1.14 mL/200 mg q2w 2.0 mL/300 mg q2w
Placebo (n [ 63) Dupilumab (n [ 126) Placebo (n [ 70) Dupilumab (n [ 123)
Baseline, n 53 115 62 107
Mean (SD) 44.77 (19.75) 41.30 (17.98) 43.81 (19.28) 42.76 (18.02)
Week 12, n 51 113 61 102
LS mean (SE) 5.68 (2.21) 13.81 (1.49) 9.75 (2.01) 15.77 (1.57)
LS mean difference vs placebo (95% CI) 8.13 (13.28 to 2.98) 6.02 (10.93 to 1.10)
P value .0021 .0166
Week 24, n 52 111 58 102
LS mean (SE) 6.44 (2.29) 14.71 (1.55) 7.97 (2.11) 16.76 (1.62)
LS mean difference vs placebo (95% CI) 8.27 (13.61 to 2.93) 8.79 (13.94 to 3.64)
P value .0025 .0009
Week 52, n 42 89 49 85
LS mean (SE) 4.47 (2.44) 16.35 (1.65) 7.54 (2.23) 17.86 (1.72)
LS mean difference vs placebo (95% CI) 11.88 (17.59 to 6.18) 10.32 (15.77 to 4.87)
P value <.0001 .0002
CI, Conﬁdence interval; CRS, chronic rhinosinusitis; LS, least squares; q2w, every 2 weeks; SD, standard deviation; SE, standard error; SNOT-22, Sino-Nasal Outcome Test.
P values are vs matched placebo.
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TABLE E6. Median FeNO (ppb) levels during the 52-week treatment period in patients with asthma with CRS and patients with asthma without CRS—exposed population
Patients with asthma with CRS (n [ 382) Patients with asthma without CRS (n [ 1520)
1.14 mL/200 mg q2w 2.0 mL/300 mg q2w 1.14 mL/200 mg q2w 2.0 mL/300 mg q2w
Placebo (n [ 63) Dupilumab (n [ 126) Placebo (n [ 70) Dupilumab (n [ 123) Placebo (n [ 250) Dupilumab (n [ 505) Placebo (n [ 251) Dupilumab (n [ 509)
Baseline, n 62 126 69 123 245 498 247 503
Median (95% CI) 31.0 (26.0 to 42.0) 32.0 (29.0 to 39.0) 35.0 (30.0 to 48.0) 26.0 (23.0 to 33.0) 24.0 (21.0 to 27.0) 21.0 (19.0 to 23.0) 24.0 (21.0 to 29.0) 24.0 (21.0 to 25.0)
Week 2, n 61 116 63 114 230 462 229 475
Median (95% CI) 31.0 (23.0 to 43.0) 20.0 (17.0 to 24.0) 38.0 (30.0 to 40.0) 18.0 (17.0 to 21.0) 23.0 (21.0 to 26.0) 16.0 (15.0 to 17.0) 23.0 (21.0 to 27.0) 16.0 (15.0 to 17.0)
P value <.0001 <.0001 <.0001 <.0001
Week 12, n 58 119 68 109 228 465 230 467
Median (95% CI) 32.5 (28.0 to 38.0) 19.0 (16.0 to 23.0) 35.5 (29.0 to 47.0) 18.0 (15.0 to 19.0) 23.0 (20.0 to 25.0) 15.0 (14.0 to 16.0) 21.0 (19.0 to 23.0) 14.0 (14.0 to 15.0)
P value .0002 <.0001 <.0001 <.0001
Week 24, n 57 116 61 109 220 446 223 452
Median (95% CI) 35.0 (24.0 to 43.0) 18.0 (16.0 to 20.0) 33.0 (25.0 to 38.0) 18.0 (15.0 to 19.0) 23.5 (20.0 to 27.0) 15.0 (14.0 to 15.0) 21.0 (17.0 to 25.0) 14.0 (13.0 to 15.0)
P value .0007 <.0001 <.0001 <.0001
Week 52, n 47 92 49 82 164 342 168 344
Median (95% CI) 32.0 (25.0 to 48.0) 18.0 (15.0 to 20.0) 42.0 (25.0 to 51.0) 16.0 (15.0 to 19.0) 20.0 (18.0 to 26.0) 14.0 (13.0 to 15.0) 21.0 (19.0 to 26.0) 15.0 (14.0 to 16.0)
P value .0094 .0003 <.0001 <.0001
CI, Conﬁdence interval; CRS, chronic rhinosinusitis; FeNO, fractional exhaled nitric oxide; ICS, inhaled corticosteroid; q2w, every 2 weeks.
P values are comparing dupilumab vs matched placebo for change in FeNO from baseline and are based on rank analysis of the covariance model adjusted for baseline FeNO, age, sex, geographic region, baseline eosinophil strata, and











































TABLE E7. Median serum total IgE (IU/mL) levels during the 52-week treatment period in patients with asthma with CRS and patients with asthma without CRS
Patients with asthma with CRS (n [ 382) Patients with asthma without CRS (n [ 1520)

















Baseline, n 63 125 69 122 249 501 249 504
















Week 12, n 62 126 70 120 244 493 246 502
















P value <.0001 <.0001 <.0001 <.0001
Week 24, n 61 121 64 119 238 476 233 475
















P value <.0001 <.0001 <.0001 <.0001
Week 52, n 53 102 58 100 185 396 193 382
















P value <.0001 <.0001 <.0001 <.0001
CI, Conﬁdence interval; CRS, chronic rhinosinusitis; ICS, inhaled corticosteroid; q2w, every 2 weeks.
P values are comparing dupilumab vs matched placebo for change in serum total IgE from baseline and are based on rank analysis of the covariance model adjusted for baseline serum total IgE, age, sex, geographic region, baseline eosinophil







































TABLE E8. Median serum TARC (pg/mL) levels during the 52-week treatment period in patients with asthma with CRS and patients with asthma without CRS—exposed population
Patients with asthma with CRS (n [ 382) Patients with asthma without CRS (n [ 1520)
1.14 mL/200 mg q2w 2.0 mL/300 mg q2w 1.14 mL/200 mg q2w 2.0 mL/300 mg q2w





Baseline, n 63 126 69 122 244 500 250 500
Median (95% CI) 335.0
(217.0 to 367.0)




Week 12, n 63 126 70 122 244 495 247 501
Median (95% CI) 322.0
(221.0 to 401.0)




P value .0002 <.0001 <.0001 <.0001
Week 24, n 59 119 60 113 238 466 229 468
Median (95% CI) 289.0
(221.0 to 392.0)




P value .0003 <.0001 <.0001 <.0001
Week 52, n 53 102 57 100 184 396 191 379
Median (95% CI) 281.0
(231.0 to 391.0)




P value .0002 .0001 <.0001 <.0001
CI, Conﬁdence interval; CRS, chronic rhinosinusitis; ICS, inhaled corticosteroid; q2w, every 2 weeks; TARC, thymus and activation-regulated chemokine.
P values are comparing dupilumab vs matched placebo for change in serum TARC from baseline and are based on rank analysis of the covariance model adjusted for baseline TARC, age, sex, geographic region, baseline eosinophil strata,











































TABLE E9. Median blood eosinophil (Giga/L) count during the 52-week treatment period in patients with asthma with CRS and patients with asthma without CRS—exposed population
Patients with asthma with CRS (n [ 382) Patients with asthma without CRS (n [ 1520)
1.14 mL/200 mg q2w 2.0 mL/300 mg q2w 1.14 mL/200 mg q2w 2.0 mL/300 mg q2w





Baseline, n 63 126 70 123 250 504 250 509








Week 4, n 62 124 69 120 238 486 238 496








P value .1136 .1586 .0314 .5775
Week 12, n 59 120 67 113 239 475 235 482








P value .0018 .0676 .7294 .7691
Week 24, n 60 115 65 112 231 463 224 465








P value .3222 .5364 .0768 .5150
Week 52, n 52 94 57 96 183 371 188 380








P value .0519 .7685 .0121 .2433
ANCOVA, Analysis of covariance; CI, conﬁdence interval; CRS, chronic rhinosinusitis; ICS, inhaled corticosteroid; q2w, every 2 weeks.
P values are comparing dupilumab vs matched placebo for change in blood eosinophil count from baseline and are based on the rank ANCOVA model adjusted for baseline blood eosinophil count, age, sex, geographic region, baseline
eosinophil strata, and baseline ICS dose level. JA
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